Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Individualized Chemotherapy Selection in Advanced Pancreatic Carcinoma
NCT01454180Phase 2Completed
- Sponsor
- Spanish National Cancer Research Centre
- Start
- Oct 2011
- Primary completion
- Oct 2011
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of gemcitabine, capecitabine, erlotinib, oxaliplatin, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in pancreatic carcinoma, sponsored by Spanish National Cancer Research Centre. Started Oct 2011; status: completed.
02
Drugs
gemcitabinecapecitabineerlotiniboxaliplatinirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
pancreatic carcinoma
Beyond the preview
Go deeper on NCT01454180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01454180.